Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients

Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts